Five years' experience with a peripheral veno-arterial ECMO for mechanical bridge to heart transplantation.
Heart transplantation
extracorporeal membrane oxygenation
mechanical circulatory support
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
12
6
2019
Statut:
ppublish
Résumé
Mechanical circulatory support (MCS) is the only way to save a life for heart transplant candidates and to decrease of waiting list mortality. The choice between short- or long-term pretransplant MCS depends on of type and severity of CHF. One of the most frequently used methods of temporary MSC before orthotopic heart transplantation (OHTx) is veno-arterial extracorporeal membrane oxygenation (VA ECMO). The aim of this study was to analyze own experience of peripheral VA ECMO (pVA ECMO) in heart transplant candidates needed in urgent HT. This study included 182 pts [160 (87.9%) men and 22 (12.1%) female, age 43±1.2 yrs] supported with pVA ECMO in the period from 01. 01. 2013 to 31. 12. 2017 or 23.2% from all waiting list (n=786). During VA ECMO, 16 (8.8%) of the 182 pts died. In most pts [n=13 (81.3%)] multiorgan failure/sepsis were the cause of death. One hundred and sixty-six (91.2%) pts were successfully bridged to OHTx or 27.9% from all heart transplant recipients (n=594) (2013-2017 yrs). The duration of pVA ECMO before OHTx (n=166) was 5.8±3.2 days. One hundred and forty-three (86.1%) from 166 pts were discharged to home. Post-transplant survival among heart transplant recipient with pre-transplant MCS by pVA ECMO was in comparison with recipients without pretransplant MCS [84.2% pVA ECMO is a useful tool of treatment of patients with INTERMACS profile 1/2. Results of OHTx at recipients bridged with VA ECMO are less successful that recipients without pre-transplant MCS. VA ECMO should be considered as a direct bridge to OHTx in conditions of limited financial resources of health care and high availability of donor's hearts.
Sections du résumé
BACKGROUND
BACKGROUND
Mechanical circulatory support (MCS) is the only way to save a life for heart transplant candidates and to decrease of waiting list mortality. The choice between short- or long-term pretransplant MCS depends on of type and severity of CHF. One of the most frequently used methods of temporary MSC before orthotopic heart transplantation (OHTx) is veno-arterial extracorporeal membrane oxygenation (VA ECMO). The aim of this study was to analyze own experience of peripheral VA ECMO (pVA ECMO) in heart transplant candidates needed in urgent HT.
METHODS
METHODS
This study included 182 pts [160 (87.9%) men and 22 (12.1%) female, age 43±1.2 yrs] supported with pVA ECMO in the period from 01. 01. 2013 to 31. 12. 2017 or 23.2% from all waiting list (n=786).
RESULTS
RESULTS
During VA ECMO, 16 (8.8%) of the 182 pts died. In most pts [n=13 (81.3%)] multiorgan failure/sepsis were the cause of death. One hundred and sixty-six (91.2%) pts were successfully bridged to OHTx or 27.9% from all heart transplant recipients (n=594) (2013-2017 yrs). The duration of pVA ECMO before OHTx (n=166) was 5.8±3.2 days. One hundred and forty-three (86.1%) from 166 pts were discharged to home. Post-transplant survival among heart transplant recipient with pre-transplant MCS by pVA ECMO was in comparison with recipients without pretransplant MCS [84.2%
CONCLUSIONS
CONCLUSIONS
pVA ECMO is a useful tool of treatment of patients with INTERMACS profile 1/2. Results of OHTx at recipients bridged with VA ECMO are less successful that recipients without pre-transplant MCS. VA ECMO should be considered as a direct bridge to OHTx in conditions of limited financial resources of health care and high availability of donor's hearts.
Identifiants
pubmed: 31183168
doi: 10.21037/jtd.2019.02.55
pii: jtd-11-S6-S889
pmc: PMC6535486
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S889-S901Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Artif Organs. 2001 Aug;25(8):599-602
pubmed: 11531708
Circulation. 2007 Mar 27;115(12):1563-70
pubmed: 17353436
Clin Transplant. 2010 May-Jun;24(3):375-80
pubmed: 19744095
Clin Transplant. 2012 May-Jun;26(3):484-8
pubmed: 21919969
J Thorac Cardiovasc Surg. 2012 May;143(5):1193-7
pubmed: 22365064
Clin Cardiol. 2013 Jul;36(7):378-82
pubmed: 23595910
Int J Cardiol. 2014 Sep;176(1):86-93
pubmed: 25034802
ASAIO J. 2015 Jan-Feb;61(1):31-6
pubmed: 25303799
ASAIO J. 2015 Mar-Apr;61(2):139-43
pubmed: 25396273
Ann Cardiothorac Surg. 2014 Sep;3(5):513-24
pubmed: 25452913
J Heart Lung Transplant. 2015 Oct;34(10):1244-54
pubmed: 26454738
J Heart Lung Transplant. 2016 Jan;35(1):1-23
pubmed: 26776864
Am J Emerg Med. 2016 Jul;34(7):1294-301
pubmed: 27162114
Transplantation. 2016 Sep;100(9):1979-87
pubmed: 27306536
J Cardiothorac Vasc Anesth. 2016 Jun;30(3):619-26
pubmed: 27321789
J Heart Lung Transplant. 2017 Jan;36(1):77-81
pubmed: 27866925
JACC Heart Fail. 2017 Feb;5(2):110-119
pubmed: 28017351
Eur J Cardiothorac Surg. 2017 Feb 1;51(2):271-278
pubmed: 28186235
Eur J Heart Fail. 2017 May;19(5):595-602
pubmed: 28198133
ESC Heart Fail. 2018 Feb;5(1):75-86
pubmed: 28741873
Eur J Heart Fail. 2018 Jan;20(1):178-186
pubmed: 28949079
J Heart Lung Transplant. 2018 Jan;37(1):1-6
pubmed: 29132918
Artif Organs. 2018 Jun;42(6):670-673
pubmed: 29392738
Herz. 2018 Aug;43(5):406-414
pubmed: 29808277